News

The 3rd Annual Meeting of IMMUTOL was hosted and organised by INN-Acta in Siena, Italy, between 20th and 21st of May 2026. The meeting provided a valuable opportunity for in-person discussions, sharing results, and planning future activities during dedicated brainstorming sessions. It also served to prepare for the reporting and review meeting. A significant aspect of the event was a…

Jana Willemyns (IGTP) participated in the 46th Congress of the Spanish Society of Immunology (Sociedad Española de Inmunología, SEI), which took place in Cordoba, Spain, from April 16th to 18th, 2026. She presented her work in poster entitled: Assessing the in vivo efficacy of IL-10 engineered Vitamin D3-tolerogenic dendritic cells in the experimental autoimmune encephalomyelitis…

Liubov Babii & Daniëlle ter Braake from SQ presented a poster at the NVVI conference in 2025, Noordwijkerhout, The Netherlands. The poster was focused on how VitD3DCIL-10 modulate B cell responses in a T cell-dependent manner. At the NVVI, Immunologists from all over the Netherlands come together to discuss immunology research, and therefore, this provides…

Liubov Babii & Daniëlle ter Braake from SQ presented a poster at the Sanquin Science Day to show their data on the T cell-independent effect of VitD3DCIL-10 on B cells. The meeting was an excellent opportunity to discuss the findings, plans and to gather new insights into possible techniques SQ already has in-house.

Alex Agúndez Moreno and Eva Martínez-Cáceres from IGTP represented IMMUTOL at the XIX Congress of the Catalan Society of Immunology, SCI 2025, 20-21st November 2025, Barcelona, Spain. LINK: https://sci.cat/?p=page/html/detallactivitat/id/27307/codi_entitat/022/tipus_entitat/s

Attila Imre (SRI) presented a poster entitled: Early stage health economic evaluation of IMMUTOL gene Therapy for relapsing/remitting Multiple Sclerosis in the Netherlands at ISPOR Europe 2025, 9-12 November 2025, Glasgow, Scotland, UK. Link to event page Poto: SRI ISPORE 2025

Alex Agundez-Moreno and Eva Martínez-Cáceres from the IGTP team represented IMMUTOL at the meeting of the Federation of Clinical Immunology Societies (FOCIS) 2025, Rouen, France, 20-24th October 2025. Eva gave a talk entitled: Cell-based tolerogenic therapies in autoimmune diseases and Alex presented a poster entitled: Immune monitoring antigen-specific autoreactive T-cell responses in a cohort of…

41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) was held between September 24th–26th in Barcelona, Spain. IMMUTOL was represented by team members from the Institut de Recerca Germans Trias i Pujol (IGTP): Alex Agúndez Moreno and Cristina Ramo Tello, along with our collaborator, the European Multiple Sclerosis Platform (EMSP).

Sara presented her work on the development of an advanced cell therapy based on antigen-specific tolerogenic dendritic cells (TolDCs) to re-establish immune tolerance in immune-mediated diseases. Event website

The paper recently published in the British Journal of Clinical Pharmacology is entitled: Early-stage health technology assessment of a curative gene therapy for multiple sclerosis. Link to the article: http://doi.org/10.1002/bcp.70204 As indicated in the paper abstract, the authors conclude that ‘IMMUTOL gene therapy shows promising cost-effectiveness at a value-based price up to approximately €500 000, contingent on achieving curative clinical efficacy.…